Form 4 for DGX Quest Diagnostics
Accepted 2024-03-01 00:00:00 ET · period of report 2024-02-28 · accession 0001022079-24-000079 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-01 | 2024-02-28 | DGX | GARDNER MARK A | SVP of Molecular Gen, Oncol | F - Tax | $126.36 | -262 | 4,793 | -5% | -$33.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-28 | F | D | 262 | $126.36 | 4,793 | D | — | — | (F1) Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. |